Use of anti-cd100 antibodies
CA 2514226 C · Owner: Giraudon, Pascale · Inventors: Giraudon, Pascale; Bensussan, Armand; Belin, Marie-Francoise
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof or a fragment thereof, for the , therapy or diagnosis of a central nervous system disorder more particularly a , myelin disorder or a disease that affects oligodendrocytes such as multiple , sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 2, 2004 and granted April 28, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 2, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 2, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.